CST will conduct in vivo phosphorylation profiling of a small molecule kinase inhibitor response in xenograft tumor models.
Cell Signaling Technology (CST) and Bristol-Myers Squibb agreed to continue their research agreement related to phosphor-profiling Bristol-Myers Squibb’s kinase inhibitor.
The companies report that the project will build on a successful evaluation, which was completed in March 2007. It will involve in vivo phosphorylation profiling of a small molecule kinase inhibitor response in xenograft tumor models.
PhosphoScan profiling involves immunoaffinity purification and tandem mass spectroscopy. The PhosphoSignatures™ generated with the Bristol-Myers Squibb compound will be analyzed and understood within the context of CST’s PhosphoSignature database, reportedly covering hundreds of cancer cell lines and human tumors.
“The application of PhosphoScan to both cell and tumor models is an effective strategy by which to validate PhosphoSignature discoveries, enabling the opportunity to develop biomarker assays specific for Bristol-Myers Squibb targeted small molecule therapeutics,” says Christopher Bunker, CST’s director of business development.